Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several
phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and
other tumors also showed apatinib has less toxic side effects and better patient tolerance.
However, the clinical application of apatinib in small cell lung cancer is still lack of
evidence-based medicine. Etoposide and cisplatin chemotherapy is the first-line treatment for
small-cell lung cancer. The purpose of this multicenter, randomized, prospective study is to
investigate the efficacy and safety of apatinib as the maintenance therapy for extensive
stage small cell lung cancer after combined with etoposide and cisplatin chemotherapy.